Diego Penas-Rodriguez

Santiago De Compostela, GA, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Corrigendum to "Real-World Impact of GLP-1 Receptor Agonists on Health-Related Quality of Life in Type 2 Diabetes and Obesity (SEVERAL Study)" [Clin Ther. 2026;48:291-293].

Corrigendum to "Real-World Impact of GLP-1 Receptor Agonists on Health-Related Quality of Life in Type 2 Diabetes and Obesity (SEVERAL Study)" [Clin Ther. 2026;48:291-293].

Journal: Clinical therapeutics

Published: May 23, 2026

Comparative pharmacovigilance analysis of suicidality-related adverse events among GLP-1 and non-GLP-1 anti-obesity drugs in the FDA Adverse Event Reporting System.

Comparative pharmacovigilance analysis of suicidality-related adverse events among GLP-1 and non-GLP-1 anti-obesity drugs in the FDA Adverse Event Reporting System.

Journal: International journal of clinical pharmacy

Published: November 14, 2025

Real-world Impact of GLP-1 Receptor Agonists on Health-related Quality of Life in Type 2 Diabetes and Obesity (SEVERAL Study).

Real-world Impact of GLP-1 Receptor Agonists on Health-related Quality of Life in Type 2 Diabetes and Obesity (SEVERAL Study).

Journal: Clinical therapeutics

Published: November 08, 2025

Effects of GLP-1 agonists on 10-year cardiovascular risk reduction in primary prevention: A 44-week open label prospective study.

Effects of GLP-1 agonists on 10-year cardiovascular risk reduction in primary prevention: A 44-week open label prospective study.

Journal: Diabetes & metabolic syndrome

Published: November 19, 2024

Cost-Utility Analysis of PCSK9 Inhibitors and Quality of Life: A Two-Year Multicenter Non-Randomized Study.

Cost-Utility Analysis of PCSK9 Inhibitors and Quality of Life: A Two-Year Multicenter Non-Randomized Study.

Journal: Diseases (Basel, Switzerland)

Published: August 12, 2024

Meteorin-like protein plasma levels are associated with worse outcomes in de novo heart failure.

Meteorin-like protein plasma levels are associated with worse outcomes in de novo heart failure.

Journal: European journal of clinical investigation

Published: August 06, 2024

Cardiometabolic effects of sacubitril/valsartan in a rat model of heart failure with preserved ejection fraction.

Cardiometabolic effects of sacubitril/valsartan in a rat model of heart failure with preserved ejection fraction.

Journal: Biochemical pharmacology

Published: April 16, 2024

Human recombinant relaxin-2 (serelaxin) regulates the proteome, lipidome, lipid metabolism and inflammatory profile of rat visceral adipose tissue.

Human recombinant relaxin-2 (serelaxin) regulates the proteome, lipidome, lipid metabolism and inflammatory profile of rat visceral adipose tissue.

Journal: Biochemical pharmacology

Published: January 14, 2024

Observational multicentre prospective study to assess changes in cognitive function in patients treated with PCSK9i. Study protocol.

Observational multicentre prospective study to assess changes in cognitive function in patients treated with PCSK9i. Study protocol.

Journal: Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria

Published: May 04, 2021

Relaxin activates AMPK-AKT signaling and increases glucose uptake by cultured cardiomyocytes.

Relaxin activates AMPK-AKT signaling and increases glucose uptake by cultured cardiomyocytes.

Journal: Endocrine

Published: August 10, 2017

Relaxin-2 in Cardiometabolic Diseases: Mechanisms of Action and Future Perspectives.

Relaxin-2 in Cardiometabolic Diseases: Mechanisms of Action and Future Perspectives.

Journal: Frontiers in physiology

Published: May 29, 2017

Metabolic alterations derived from absence of Two-Pore Channel 1 at cardiac level.

Metabolic alterations derived from absence of Two-Pore Channel 1 at cardiac level.

Journal: Journal of biosciences

Published: December 15, 2016

Showing 1-12 of 18

Last Updated: 09/26/2026